In this study, we investigated the anti-diabetic effect of Aster sphathulifolius (AS) extract in C57BL/KsJ-db/db mice. The db/db mice were orally administered with AS 50% ethanol extract at concentrations of 50, 100, and 200 mg/kg/day (db/db-AS50, db/db-AS100, and db/db-AS200, respectively) for 10 weeks. Food and water intake, fasting blood glucose concentrations, blood glycosylated hemoglobin levels, and plasma insulin levels were significantly lower in the db/db-AS200 group than in the vehicle-treated db/db group; whereas glucose tolerance was significantly improved in the db/db-AS200 group. Moreover, AS dose dependently increased both insulin receptor substrate 1 and glucose transporter type 4 expression in skeletal muscle, significantly increased glucokinase expression, and decreased glucose 6-phosphatase and phosphoenolpyruvate carboxykinase expressions in the liver. The expressions of transcription factors, such as sterol-regulatory element-binding protein, peroxisome proliferator-activated receptor γ, and adipocyte protein 2, were upregulated in adipose tissue. Furthermore, immunohistochemical analysis showed that AS upregulated insulin production by increasing pancreatic β-cell mass. In summary, AS extract normalized hyperglycemia by multiple mechanisms: inhibition of glyconeogenesis, acceleration of glucose metabolism and lipid metabolism, and increase of glucose uptake. Using in vivo assays, this study has shown the potential of AS as a medicinal food and suggests the efficacy of AS for the use of prevention of diabetes.
Get full access to this article
View all access options for this article.
References
1.
DeFronzoRA: Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: A balanced overview. Diabetologia, 1992; 35:389–397.
2.
Yki-JarvinenH: Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet, 1994; 343:91–95.
3.
FerreT, PujolA, RiuE, BoschF, ValeraA: Correction of diabetic alterations by glucokinase. Proc Natl Acad Sci USA, 1996; 93:7225–7230.
4.
ReavenGM: Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabetes Metab Rev, 1993; 9:5S–12S.
5.
BjornholmM, ZierathJR: Insulin signal transduction in human skeletal muscle: Identifying the defects in Type II diabetes. Biochem Soc Trans, 2005; 33:354–357.
6.
ZismanA, PeroniOD, AbelED, et al.: Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med, 2000; 6:924–928.
7.
SaltielAR, KahnCR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 2001; 414:799–806.
8.
DeFronzoRA, JacotE, JequierE, MaederE, WahrenJ, FelberJP: The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes, 1981; 30:1000–1007.
9.
CarvalhoE, KotaniK, PeroniOD, KahnBB: Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am J Physiol Endocrinol Metab, 2005; 289:E551–E561.
10.
PosticC, ShiotaM, NiswenderKD, et al.: Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem, 1999; 274:305–315.
11.
ChatelainF, PegorierJP, MinassianC, et al.: Development and regulation of glucose-6-phosphatase gene expression in rat liver, intestine, and kidney: in vivo and in vitro studies in cultured fetal hepatocytes. Diabetes, 1998; 47:882–889.
12.
O'BrienRM, GrannerDK: PEPCK gene as model of inhibitory effects of insulin on gene transcription. Diabetes Care, 1990; 13:327–339.
13.
MuoioDM, NewgardCB: Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol, 2008; 9:193–205.
14.
TontonozP, KimJB, GravesRA, SpiegelmanBM: ADD1: A novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol, 1993; 13:4753–4759.
15.
HortonJD, ShimomuraI: Sterol regulatory element-binding proteins: Activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol, 1999; 10:143–150.
16.
FajasL, SchoonjansK, GelmanL, et al.: Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: Implications for adipocyte differentiation and metabolism. Mol Cell Biol, 1999; 19:5495–5503.
17.
KimJB, WrightHM, WrightM, SpiegelmanBM: ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA, 1998; 95:4333–4337.
18.
KimJB, SarrafP, WrightM, et al.: Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest, 1998; 101:1–9.
19.
FlierJS, HollenbergAN: ADD-1 provides major new insight into the mechanism of insulin action. Proc Natl Acad Sci USA, 1999; 96:14191–14192.
LunaB, FeinglosMN: Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician, 2001; 63:1747–1756.
22.
KimTJ: Wild Flowers of Korea. Kugilmedia, Seoul, Korea, 1996, p. 232.
23.
LeeCB: Illustrated Flora of Korea. Hyangmoonsa, Seoul, Korea, 1999, p. 740.
24.
WonJN, LeeSY, SongDS, PooH: Antiviral activity of the plant extracts from Thuja orientalis, Aster sphathulifolius, and Pinus thunbergii against influenza virus A/PR/8/34. J Microbiol Biotechnol, 2013; 23:125–130.
25.
LeeSO, ChoiSZ, ChoiSU, et al.: Labdane diterpenes from Aster sphathulifolius and their cytotoxic effects on human cancer cell lines. J Nat Prod, 2005; 68:1471–1474.
26.
KleinR: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 1995; 18:258–268.
27.
LarsenML, HorderM, MogensenEF: Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med, 1990; 323:1021–1025.
28.
StrattonIM, AdlerAI, NeilHA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ, 2000; 321:405–412.
29.
HansenME, TippettsTS, AndersonMC, et al.: Insulin increases ceramide synthesis in skeletal muscle. J Diabetes Res, 2014; 2014:765–784.
30.
CoomansCP, GeerlingJJ, GuigasB, et al.: Circulating insulin stimulates fatty acid retention in white adipose tissue via KATP channel activation in the central nervous system only in insulin-sensitive mice. J Lipid Res, 2011; 52:1712–1722.
31.
HiriartM, Sanchez-SotoC, Diaz-GarciaCM, et al.: Hyperinsulinemia is associated with increased soluble insulin receptors release from hepatocytes. Front Endocrinol (Lausanne), 2014; 5:95.
32.
OdeleyeOE, de CourtenM, PettittDJ, RavussinE: Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. Diabetes, 1997; 46:1341–1345.
33.
LiuJ, WuYY, HuangXM, et al.: Ageing and type 2 diabetes in an elderly chinese population: The role of insulin resistance and beta cell dysfunction. Eur Rev Med Pharmacol Sci, 2014; 18:1790–1797.
34.
CamposG, RyderE, Diez-EwaldM, et al.: Prevalence of obesity and hyperinsulinemia: Its association with serum lipid and lipoprotein concentrations in healthy individuals from Maracaibo, Venezuela. Invest Clin, 2003; 44:5–19.
35.
HansenJ, RinnovA, Krogh-MadsenR, et al.: Plasma follistatin is elevated in patients with type 2 diabetes: Relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation. Diabetes Metab Res Rev, 2013; 29:463–472.
36.
Van ObberghenE, BaronV, DelahayeL, et al.: Surfing the insulin signaling web. Eur J Clin Invest, 2001; 31:966–977.
37.
JamesDE, StrubeM, MuecklerM: Molecular cloning and characterization of an insulin-regulatable glucose transporter. Nature, 1989; 338:83–87.
PessinJE, SaltielAR: Signaling pathways in insulin action: Molecular targets of insulin resistance. J Clin Invest, 2000; 106:165–169.
40.
McGarryJD: Disordered metabolism in diabetes: Have we underemphasized the fat component?. J Cell Biochem, 1994; 55:29–38.
41.
PirgonO, BilginH, CekmezF, KurkuH, DundarBN: Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol, 2013; 5:33–39.
42.
MatschinskyFM: Regulation of pancreatic beta-cell glucokinase: From basics to therapeutics. Diabetes, 2002; 51:S394–S404.
43.
SeoaneJ, BarberaA, Telemaque-PottsS, NewgardCB, GuinovartJJ: Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats. J Biol Chem, 1999; 274:31833–31838.
44.
MisawaE, TanakaM, NomaguchiK, et al.: Oral ingestion of aloe vera phytosterols alters hepatic gene expression profiles and ameliorates obesity-associated metabolic disorders in zucker diabetic fatty rats. J Agric Food Chem, 2012; 60:2799–2806.
45.
AchesonKJ, SchutzY, BessardT, RavussinE, JequierE, FlattJP: Nutritional influences on lipogenesis and thermogenesis after a carbohydrate meal. Am J Physiol, 1984; 246:E62–E70.
46.
FerreP, FoufelleF: Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab, 2010; 12:83–92.
47.
FerreP: The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes, 2004; 53:S43–S50.
48.
BaxaCA, ShaRS, BueltMK, et al.: Human adipocyte lipid-binding protein: Purification of the protein and cloning of its complementary DNA. Biochemistry, 1989; 28:8683–8690.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
